Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Rodman & Renshaw Global Investment Conference 2018
26 slides from Prescient Therapeutics's conference presentation, Sep 5, 2018
Slide 1: Overcoming the Challenges of Known Cancer Pathways with Novel Targeted Therapies
For personal use only OVERCOMING THE CHALLENGES OF KNOWN CANCER PATHWAYS WITH NOVEL TARGETED THERAPIES Prescient Therapeutics Limited (ASX: PTX) RODMAN & RENSHAW CONFERENCE SEPTEMBER 2018
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Investment Summary
INVESTMENT SUMMARY For personal use only • Novel targeted (precision) cancer therapies overcoming limitations of previous approaches to problematic pathways • Multiple shots on goal: Akt inhibitor in 3 trials; preparing a 4th transformative study in Ras/Rho mutant cancers • Robust body of science un
Slide 4: Deep, Clinical Stage Pipeline
DEEP, CLINICAL STAGE PIPELINE For personal use only • PTX-200 currently in three clinical trials • Advancing PTX-100 in Rho & Ras mutant cancers - a transformative opportunity DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE 2 PHASE 3 PTX-200 BREAST CANCER PTX-200 OVARIAN CANCER PTX-200 AML P
Slide 5: Corporate Snapshot
CORPORATE SNAPSHOT For personal use only KEY METRICS ASX Ticker PTX Market Capitalisation1 A$20 M (US$14.3 M) Total Issued Capital 211.3 M shares Cash Position2 A$5.5 M (US$4.0 M) Options 57.8 M Top 20 Own 52% Share Price1 A$0.093 (US$0.07) 6 month turnover 22.7 M shares; A$1.6 M (US$1.3 M) SHARE PR
Slide 6: PTX-200 Novel Akt Inhibition
PTX-200 For personal use only NOVEL AKT INHIBITION Breast cancer AML Ovarian cancer 6 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 7: PTX-200 Novel Akt Inhibition
PTX-200 NOVEL AKT INHIBITION OVERCOMING LIMITATIONS OF PREVIOUS ATTEMPTS AT AKT INHIBITION For personal use only • Novel mechanism of action • Highly selective • Anti-proliferative AND pro-apoptotic • Selectively inhibits regulatory T cells • Overcomes chemo-resistance • Biomarker of PTX-200 clinica
Slide 8: PTX-200: Novel Akt Inhibition via PH Domain Binding
PTX-200: NOVEL AKT INHIBITION VIA PH DOMAIN BINDING For personal use only • PTX-200 is NOT an ATP mimic/direct kinase inhibitor » avoids off-target effects associated with ATP mimic inhibitors. • PTX-200 binds to the PH domain prevents Akt binding to the plasma membrane inactivates Akt Control P
Slide 9: Akt Plays a Key Role in HER2- Breast Cancer
AKT PLAYS A KEY ROLE IN HER2 - BREAST CANCER For personal use only 80% OF BREAST CANCERS ARE HER2- BUT THIS IS STILL UNDERSERVED BY NEW DRUGS $10.6B MARKET NEED: $5.4B LACK OF PIPELINE AGENTS ADDRESSING » RESISTANT ER+ DISEASE » NEOADJUVANT THERAPY 41% Generics 2015 2025 PTX’S NICHE: NEOADJUVANT » A
Slide 10: Phase 1b Breast Cancer Trial Successfully Completed; Now in Phase 2
PHASE 1B BREAST CANCER TRIAL SUCCESSFULLY COMPLETED; NOW IN PHASE 2 For personal use only • PTX-200 in combination with paclitaxel, followed by AC (doxorubicin & cyclophosphamide) • Patients with metastatic and locally advanced HER2- breast cancer Joseph Sparano, M.D. Principal Investigator • 28 pat
Slide 11: What Does Success Look Like for This Disease?
WHAT DOES SUCCESS LOOK LIKE FOR THIS DISEASE? For personal use only • Studies on all sub-types of locally advanced breast cancer receiving weekly chemo reports a wide range of pCR (8-28%) • For women with locally advanced ER+, HER2 negative breast cancer, typical expectations are: » pCR of 16% (11-2
Slide 12: Phase 1b Efficacy Results Very Encouraging
PHASE 1B EFFICACY RESULTS VERY ENCOURAGING For personal use only Metastatic & locally advanced patients Locally advanced patients ER+ Triple Total ER+ Triple Total negative negative pCR/CR 2 0 2 pCR/CR 2 0 2 PR 1 2 3 PR 1 2 3 SD 1 2 3 SD 0 0 0 PD 0 2 2 PD 0 0 0 ORR 75% 33% 50% ORR 100% Visual repres
Slide 13: PTX-200 in AML – Executive Summary
PTX-200 IN AML – EXECUTIVE SUMMARY For personal use only • Akt is highly relevant in AML • PTX-200 address the “phenotype, not the genotype” in AML mutations • Like other recent successful strategies in AML, PTX-200 is a targeted therapy complementing a “backbone” of standard chemotherapy • PTX-200
Slide 14: Mutational Complexity of AML
MUTATIONAL COMPLEXITY OF AML For personal use only • AML is a mutationally complex disease. It is exacerbated by the fact that mutations may be gained or lost at relapse • Many different types of mutations (and combinations of mutations) result in hyperphosphorylation of Akt » In fact, 72% of AML pa
Slide 15: High p-Akt Correlated with Inferior Survival in AML
HIGH P-AKT CORRELATED WITH INFERIOR SURVIVAL IN AML For personal use only » p-Akt/Akt correlated with » PTX-200 reduces pAkt inferior survival in AML patients’ in AML blasts 15 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 16: Phase 1b Trial Underway: Acute Myeloid Leukemia
PHASE 1B TRIAL UNDERWAY: ACUTE MYELOID LEUKEMIA For personal use only • Phase 1 results with PTX-200 (monotherapy) very encouraging • Now PTX-200 + cytarabine in refractory or relapsed acute leukemia • Professor Jeff Lancet at Moffitt Cancer Center leading the trial Jeffrey E Lancet, M.D. • Yale Can
Slide 17: Phase 1b Ovarian Cancer Trial Underway
PHASE 1B OVARIAN CANCER TRIAL UNDERWAY For personal use only • Significant need for new products to treat platinum-resistant ovarian cancer • Testing PTX-200 plus carboplatin in patients with platinum resistant ovarian cancer • PTX-200 already proven overcome cisplatin resistance and synergize with
Slide 18: PTX-100: Phase 1 in Solid Tumors Completed
PTX-100 For personal use only PHASE 1 IN SOLID TUMORS COMPLETED NOW PURSUING A TRANSFORMATIVE OPPORTUNITY IN RAS & RHO MUTANT CANCERS 18 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 19: PTX-100 First in Class, First in Man GGT-1 Inhibitor of Ras Pathway
PTX-100 FIRST IN CLASS, FIRST IN MAN GGT-1 INHIBITOR OF RAS PATHWAY For personal use only • Single agent activity in mouse models of various cancers • Combination therapy is also very effective, efficacy in mutant Ras tumors • Reduces cancer stem cell population in animal models • p27 a potential co
Slide 20: Ras Pathway Is an Important but Elusive Target
RAS PATHWAY IS AN IMPORTANT BUT ELUSIVE TARGET For personal use only GROWTH FACTOR RECEPTOR TYR KINASE • Ras mutated in 30% of all human cancers and 90% in certain cancers SoS Grb2 » 3 million new cancers diagnosed worldwide Ras FGTI each year with Ras mutations PI3K • Mutant Ras tumors are often un
Slide 21: PTX-100 Is a Highly Effective Anti Tumor Agent in Pre-Clinical Models
PTX-100 IS A HIGHLY EFFECTIVE ANTI TUMOR AGENT IN PRE-CLINICAL MODELS AND PATIENT FRESH BIOPSIES For personal use only Lung tumor1 • PTX-100 inhibits tumor growth and metastasis, 1200 induces tumor regression, and increases 1000 survival in various mouse models: Vehicle 800 » Inhibits tumor growth i
Slide 22: AITL Is a Rare Disease with Few Treatment Options and Poor Prognosis
AITL IS A RARE DISEASE WITH FEW TREATMENT OPTIONS AND POOR PROGNOSIS For personal use only • Angioimmunoblastic T-cell lymphoma (AITL) is rare, aggressive type of T-cell lymphoma • Mostly effects the elderly • Accounts for 1-2% of all non-Hodgkin lymphomas • Estimate ~ 1,000 new cases in US per year
Slide 23: RhoA Mutations Play a Prominent Role in TCL Pathogenesis
RHOA MUTATIONS PLAY A PROMINENT ROLE IN TCL PATHOGENESIS For personal use only Schematic of RhoA protein structure, with alterations • RhoA G17V mutation is a driver of pathogenesis of AITL, PTCL-NOS • Other RhoA mutations driver a number of other malignancies • PTX-100 a pan RhoA inhibitor regardle
Slide 24: PTX-100 the Only Drug Targeting RhoA
PTX-100 THE ONLY DRUG TARGETING RHOA For personal use only • Only RhoA inhibitor in the clinic • Phase 1 trial in solid tumours completed • PTX-100 has a unique position in RhoA mutant malignancies Unmet clinical need (AITL & other TCLs) PTX Mutation Only drug recently addressing identified the muta
Slide 25: Investment Summary
INVESTMENT SUMMARY For personal use only • Novel targeted (precision) cancer therapies overcoming limitations of previous approaches to problematic pathways • Multiple shots on goal • Robust body of science underpinning programs • Seasoned scientific and clinical team with a proven record of success
Slide 26: Contact
For personal use only CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com 26 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Prescient Therapeutics — Rodman & Renshaw Global Investment Conference 2018 on 6ix